Galectin Therapeutics Inc. (GALT)

3,3700 0,0000 (0,00%) Alla chiusura: 04:00PM EDT

Galectin Therapeutics Inc.

4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
(678) 620-3186
https://galectintherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 28

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Joel Lewis	President, CEO & Director	907,72k	N/D	1970
Mr. Jack W. Callicutt CPA	CFO, Treasurer & Corporate Secretary	521,47k	N/D	1967
Dr. Pol F. Boudes M.D., Ph.D.	Chief Medical Officer	730,33k	N/D	1957
Robert Tritt	General Counsel	N/D	N/D	N/D
Mr. Jeff Katstra	Head of CMC & Pharmaceutical Development	N/D	N/D	N/D
Ms. Beth Knowles	Executive Assistant & Officer Manager	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Governance aziendale

L'ISS Governance QualityScore di Galectin Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.